Danimer Scientific (DNMR) investor relations material

Executive summary

• Leadership transition underway with an interim CEO focused on leveraging industry experience and strengthening commercial execution.

• Q3 2024 sales declined by $2.3M year-over-year, mainly due to lower PHA sales from the Starbucks straw resin reapportionment and reduced PLA sales from decreased customer demand.

• Cost reduction efforts and headcount rationalization were implemented to preserve liquidity amid ongoing losses.

• The company faces substantial doubt about its ability to continue as a going concern due to negative cash flows and limited liquidity.

• Construction of the Greenfield Facility remains suspended pending additional financing.

Financial highlights

• Q3 2024 revenue was $8.6 million, down from $10.9 million year-over-year.

• Q3 2024 net loss narrowed to $21.8 million from $40.2 million in Q3 2023, aided by a $6.8 million gain on loan extinguishment.

• Gross margin for Q3 2024 was negative, with gross profit percentage at -84.8% compared to -70.7% in Q3 2023.

• Adjusted EBITDA loss improved to $8.9 million from $9.3 million year-over-year.

• Unrestricted cash and cash equivalents stood at $22.2 million at quarter end.

Outlook and guidance

• Full year 2024 adjusted EBITDA expected between -$34.4 million and -$34.9 million, within prior guidance.

• Fourth quarter adjusted EBITDA projected between -$7 million and -$7.5 million.

• Full year capital expenditures expected between $8 million and $9 million.

• Anticipates significant near-term revenue growth in 2025 from new customer awards, but these revenues are uncontracted and liquidity is insufficient to sustain operations until then.

• Evaluating restructuring, additional debt or equity issuances, and asset sales to address liquidity shortfall.